

Consolidated Financial Highlights for First Half of FY2015 (From April 1, 2015 to September 30, 2015)

Consolidated Financial Results for First Half of FY2015
 Forecast for FY2015

3. Business Strategy

November 10, 2015



Consolidated Financial Results for First Half of FY2015




1) Consolidated Financial Results for the 1st Half of FY2015

(Amounts of less than ¥1 million are rounded down)

	First half		First half FY2015			
	FY2014	Original Forecast announced May 11, 2015	Revised Forecast announced July 31, 2015	Actual	YoY (%)	
Sales	72,023	78, 500	74,000	73,498	2.0	
Domestic Sales	55,695	-	-	53,285	-4.3	-3.8% excluding the impact of transfer of transformer business
Overseas Sales	16,327	-	-	20,213	23.8	←● +9% on a local currency basis
Operating Income	5,502	6,000	3,500	4,219	-23.3	FY2014 H1 FY2015 H1 Gross margin ratio: 48.9% → 48.3%* SG&A ratio: 41.3% → 42.6%
Ordinary Income	6,096	6,000	4,000	4,401	-27.8	*Gross margin ratio improved in 2Q (3 months) FY2014 2Q FY2015 2Q
Income Attributable to Owners of Parent	4,123	4,100	2,600	2,516	-39.0	47.6% → 48.8%
Average exchange rate	First half FY2014	First half FY2015				
1 US Dollar	102.6 yen	121.6 yen				
1 EURO	138.9 yen	135.0 yen				




2) Breakdown of Operating Income





3) Sales by Product Category






3.1) Physiological Measuring Equipment

(Sales, millions of yen)						
	First half FY2014	First half FY2015	YoY (%)	Comparable YoY (%)		Domestic: Sales decreased. Overseas: Sales increased excluding the impact of reclassification.
Electroencephalographs	4,480	3,812	-14.9	-0.3		Domestic: Sales decreased.
Electrocardiographs	3,331	3,405	2.2			Overseas: Sales in Europe and Asia increased favorably.
Polygraphs for Cath Lab	4,501	5,313	18.0			Domestic: Sales of EP catheters increased. New product also contributed.
Other Physiological Measuring Equipment *	4,200	5,080	20.9	4.6	[
Physiological Measuring Equipment	16,514	17,611	6.6			
Domestic Sales	12,756	13,213	3.6			
Overseas Sales	3,757	4,397	17.0			

*Other Physiological Measuring Equipment includes diagnostic information system and products of other companies. Effective FY2015, local installed products are reclassified into Other Physiological Measuring Equipment; this was previously classified into Electroencephalographs. This reclassification was due to the ERP installation into our U.S. sales subsidiary; sales of local installed products in the 1st half FY2014 were about 0.6 billion yen.





NIHON KOHDEN

3.2) Patient Monitors

		(Sales, mill	ions of yen)	
	First half FY2014	First half FY2015	YoY (%)	
Patient Monitors	23,797	23,804	0.0	Sales decreased due to reaction to the higher
Domestic Sales	16,446	14,669	-10.8	demand in the same period last year in the private hospital market.
Overseas Sales	7,351	9,135	24.3	
		New products also contributed.		



Bedside monitors CSM-1901 New!

Bedside monitors for emerging countries SVM-7500 series



Vital sign telemeter GZ-130P



probes



Oxygen mask ECGs with CO₂ Electrodes monitoring

Consumables



3.3) Treatment Equipment

	_		_
	First half FY2014	First half FY2015	YoY (%)
Defibrillators (for Hospital and Ambulance)	2,343	2,640	12.7
AEDs (Automated External Defibrillator)	6,037	6,951	15.1
Pacemakers / ICDs	1,513	1,431	-5.4
Ventilators	679	644	-5.1
Other Treatment Equipment	3,166	2,977	-6.0
Treatment Equipment	13,739	14,645	6.6
Domestic Sales	10,496	10,348	-1.4
Overseas Sales	3,243	4,296	32.5
(Ref.) AED Unit Shipments	39,300	42,900	9.2
Domestic Unit Sales	24,600	25,300	2.8

(Sales, millions of yen)

Overseas: Sales in Americas, Europe and Asia increased favorably.

Domestic: AED unit sales increased due to demand for extension and replacement.



AED Remote Monitoring System



AED-2150, 2151, 2152

Overseas:

AED sales increased in all areas. Sales of both Defibtech and Nihon Kohden AEDs increased.

Domestic: Sales decreased due to change of cochlear implant supplier.



Defibrillators TEC-5600 series



s AEDs AED-2150



Pacemakers Zenex MRI



Ventilators HAMILTON-C1



Anesthesia Machine Leon plus



3.4) Other Medical Equipment

(Sales, millions of yen)				
	First half FY2014	First half FY2015	YoY (%)	
Hematology Analyzers	4,203	5,073	20.7	
Imaging Systems, Medical equipment for study and others *	13,767	12,363	-10.2	
Other Medical Equipment	17,971	17,437	-3.0	
Domestic Sales	15,996	15,053	-5.9	
Overseas Sales	1,974	2,383	20.7	

Domestic: Sales of hematology analyzers and clinical chemistry analyzers increased in the clinic market. **Overseas:** Sales of hematology analyzers and reagents increased favorably in Asia, especially India and the Middle East.

Domestic: Sales of locally purchased products decreased in accordance with the Company's selling policy focus on its own products.


*Includes consumables, installation and maintenance services which are not applicable to other categories. Transformer business was transferred in Sep 2014.



Automated hematology analyzers MEK-6500




Clinical chemistry analyzers CHM-4100



Installation and maintenance services



4) Domestic Sales



© Copyright NIHON KOHDEN CORPORATION All Rights Reserved




Percentage of overseas sales to

consolidated sales

5) Overseas Sales

Geographic segments

(¥100 million)





6) Financial Condition

(Amounts of less than ¥1 million are rounded down)

	FY2014	First half FY2015	Change
Current Assets	118,389	104,529	- 13,859
Fixed Assets	28,366	28,812	446
Total Assets	146,755	133,342	- 13,413
Current Liabilities	45,654	32,570	- 13,083
Non-current Fixed Liabilities	1,797	1,505	- 292
Total Liabilities	47,451	34,076	- 13,375
Net Assets	99,304	99,265	- 38
Total Liabilities & Net Assets	146,755	133,342	- 13,413



7) Capital Investments and R&D Costs

(Amounts of less than ¥1 million are rounded down)

	First half	First half		FY2	015
	FY2014	FY2015	FY2014	Original Forecast announced May 11	Revised Forecast announced Nov 4
Capital Investments	1,664	2,873	5,158	9,600	8,600
Depreciation	1,574	1,596	3,445	4,200	3,400
R&D costs	2,798	2,616	5,745	6,400	6,100

FY2015 H1 capital investments:

Molds for new products, measuring equipment and jigs, products for demonstration, production equipment and construction of Tokorozawa R&D center

FY2015 capital investments plan:

- > Molds for new products, production equipment, products for demonstration, ERP System
- Establish Tokorozawa R&D center Start of construction: Completion and relocation: Capital investments:
 Establish new facility in Asaka (Relocation of immunochemical products department) Start of construction: Completion and relocation: Capital investments:
 Feb 2016 (Plan) Winter 2016 1.1 billion yen FY2015: 0.1 billion yen FY2015: 0.1 billion yen FY2016: 1.0 billion yen



Forecast for FY2015



1) Business Environment

Japan

Japanese government 2025 future vision of medical/long-term care services

- Differentiate medical providers
- Promote home medical care and nursing care
- Establish integrated community care systems
- •0.1% upward revision of medical treatment fees and consumption tax hike in Apr 2014
 •Funds for securing comprehensive medical and long-term care in the communities FY2015: ¥162.8 bil (¥90.4 bil for medical, ¥72.4 bil for long-term care)

Government requires each prefecture to draw up a regional health vision. Deadline Mar 2018; desired mid 2016

Environmental changes cause spending restraints in the hospital market

International

Europe

Economy remains in a recovery trend

USA

Number of Americans with health insurance increased under the Affordable Care Act

Emerging Countries

- Political uncertainty and weaker currency in some regions
- Healthcare infrastructure is developing together with economic growth

Overall demand for medical equipment will remain steady



2) Measures in the 2nd Half of FY2015

Recovery of domestic business

Strengthen patient monitors business

- Receive orders for patient monitors in the university market and public hospital market
- Introduce competitive products and value-added features

Develop business respond to healthcare system reform

- Establish regional health care networks \rightarrow Focus on the private hospital market and the clinic market
- Medical Investigation System for Malpractice started in Oct 2015→Provide products and services for medical safety

Improvement of profitability

Expand sales of consumables and services

- Focus on sales of our own consumables such as SpO_2 and CO_2 sensors

Reduce costs at R&D and production

- Reduce manufacturing costs of selected models and sensors by decreasing man-hours and material costs
- Improve development efficiency by merging R&D sections for technologies which are common to all product lines
- Improve productivity by introducing automatic inspection systems and changing from a worker cell production to a group cell production

Strengthen cost control across all Nihon Kohden groups by improving expense management in each subsidiary and division, while continuing necessary investments for future international business expansion.

3) Forecast for FY2015

		FY2	015	
	FY2014	Original Forecast announced May 11	Revised Forecast announced Nov 4	YoY (%)
Sales	160,803	172,000	167,000	3.9
Domestic Sales	122,490	126,000	121,000	-1.2
Overseas Sales	38,313	46,000	46,000	20.1
Operating Income	15,921	18,000	16,500	3.6
Ordinary Income	17,234	18,000	16,800	-2.5
Income Attributable to Owners of Parent	11,142	12,100	10,700	-4.0
Percentage of overseas	23.8%	26.7%	27.5%	

(Amounts of less than ¥1 million are rounded down)

Breakdown of overseas sales by region

		FY2015		
	FY2014	Original Forecast announced May 11	Revised Forecast announced Nov 4	YoY (%)
Americas	16,423	20,000	20,300	23.6
Europe	7,495	7,700	8,300	10.7
Asia	12,581	16,100	15,200	20.8
Others	1,813	2,200	2,200	21.2


Average exchange rate

1 US Dollar	109.6 yen	118 yen	121 yen
1 EURO	139.4 yen	125 yen	135 yen

© Copyright NIHON KOHDEN CORPORATION All Rights Reserved


135 yen

4) Analysis of FY2015 Sales Forecast





5) Analysis of FY2015 Operating Income Forecast





(Ref.) Consolidated Forecast FY2015 by Product Category

(Amounts of less than ¥1 million are rounded down)

	FY2014	FY	2015	VoV (%)
	F12014	Original Forecast announced May 11	Revised Forecast announced Nov 4	YoY (%)
Physiological Measuring Equipment	37,180	40,400	40,100	7.9
Patient Monitors	53,068	59,050	56,000	5.5
Treatment Equipment	29,393	32,050	31,900	8.5
Other Medical Equipment	41,160	40,500	39,000	-5.2
Total	160,803	172,000	167,000	3.9
(Reference)				
Consumables and Services	61,426	65,750	68,300	11.2



Business Strategy




1) Long-term Vision and Mid-term Business Plan


Long-term Vision (April 2010 to March 2020)


The CHANGE 2020 -The Global Leader of Medical Solutions-

2nd Stage Strong Growth 2017

(April 2013 to March 2017)









2) Targets for FY2016 ending March 2017

		Strong Growth 2017
2016 m target	4 year CAGR	

24.6%

24.0%

18.2

2.5

¥billion		FY2012 actual	FY2015 forecast	FY2016 mid-term target	4 year CAGR
	Sales	132.5	167.0	182.0	8.3%
	Domestic	110.2	121.0	130.0	4.2%
	Overseas	22.3	46.0	52.0	23.5%
Operating Income		13.4	16.5	20.0	10.4%
ROE		12.7%		13.5%	
Breakdown of overseas sales by region Exchange rate as of plan is 118 yen to dollar and 125 yen to euro.					
	Americas	8.0	20.3	22.6	29.3%
	Europe	5.6	8.3	8.7	11.6%

15.2

2.2

7.5

1.0

Asia

Other



3) Key Strategies of Mid-term Business Plan

Strong Growth 2 0 1 7

Pursue the highest level of quality in the world

Strengthen technological development capabilities

Strengthen business expansion by region

Achieve further growth in core businesses


Develop new businesses

Consolidate corporate fundamentals



4) Strategy for FY2015(i) Achieve further growth in core businesses

New products in FY2014 and FY2015



© Copyright NIHON KOHDEN CORPORATION All Rights Reserved



4) Strategy for FY2015 (i) Achieve further growth in core businesses

Synthesized 18-lead ECG



Measurement method to derive 6-lead ECG, right-side leads and posterior leads, from the standard 12-lead ECG








Non-invasive continuous cardiac output monitoring Estimate CO using ECG and SpO₂

* esCCO : estimated Continuous Cardiac Output

Arrhythmia Analysis

High quality arrhythmia detection and reduction of <u>false alarms</u>

Nihon Kohden's original sensor technology









X NIBP : Non Invasive Blood Pressure



Pioneer in the development of principles of pulse oximetry which measures SpO₂



Oxygen masks with CO₂ monitoring

Launch 2015

CO₂ monitor

Plan to launch 2016

World's smallest and lightest mainstream CO₂ sensor

ONE etCO₂

© Copyright NIHON KOHDEN CORPORATION All Rights Reserved




Raise brand recognition through unique technologies

Fast and painless NIBP measurement by original



- New developed algorithm which measures NIBP during cuff inflation
- Quick and painless NIBP measurement



Non-invasive continuous cardiac output monitoringesCCO

- Estimate CO using ECG and SpO₂
- •No infection risk and no pain
- No additional sensors and no additional running cost

Introduce in Europe and emerging countries

Prepare for clinical research to receive PMDA and FDA approval





* esCCO : estimated Continuous Cardiac Output




Raise brand recognition through unique technologies

World's first

World's first

mainstream CO₂ sensor for non-intubated patients

cap-ONE



Oxygen masks with CO₂ monitoring

 Ensure stable oxygen supply with CO₂ monitoring


Launch infant/pediatric masks in 2012





NIHON KOHDEN

Patient Monitors








Treatment Equipment

Strengthen collaboration with patient monitors





Hematology Instruments

Find new markets Launch new products Issues in intraoperative pathological diagnosis Most advanced Hematology Analyzer hematology analyzer Judgment is subjective Lack of pathologist Takes 20 minutes Joint research with Tokyo Women's Medical University Develop intraoperative flow cytometer to support resection of glioma* during surgery **MEK-7300** Plan to launch 2016 i) Obtain tissue Tissue MEK-6500 series New! **Clinical Chemistry Analyzer** ii) Calculate the percentage of cells with high DNA content in 10 minutes CHM-4100 HbA1c and CRP CHM-4120 measurement **CRP** measurement High DNA content measuring flow cytometer FCM-2200


© Copyright NIHON KOHDEN CORPORATION All Rights Reserved

*a common type of primary brain tumor that accounts for about 30% of these tumors 30



(ii) Strengthen Business Expansion by Region

Japan: Create solutions for a national future vision of medical and nursing care services in 2025





Establish a stronger presence in the U.S. which is a center of leading-edge medical treatment

Medium size



Strengthen collaboration of 3 business and crossselling by reorganizing direct-sales operations

hospitals Neurology • Focus on top 50 hospitals in USA

Patient monitors

- Strengthen ties with GPOs and IDNs^{*} \rightarrow Negotiations increased with large IDNs and university hospitals
- Achieve 36 consecutive guarters of No. 1 customer satisfaction**
- Expand consumable sales



 CO_2 sensor





MEE-2000 Launch 2015 (USA)

Large size

hospitals



GZ-130P CSM-1901 Plan to launch FY2015

Resuscitation field

et defibtech



Nihon Kohden America expands offerings with Defibtech AEDs

Aim at 10% share in patient monitors market

* GPO: Group Purchase Organization IDN: Integrated Delivery Network

** Source: MD Buyline, Inc. which conducts a survey of U.S. hospitals for patient monitoring vendors every quarter



Increase market share in emerging markets as a key growth driver

Strengthen business structure

China

Accelerate operations by unifying development, production, sales and services

Focus on the private hospital market

Asia, the Middle East and Latin America


Enhance local sales and service network

Sales offices

Asia: China, Singapore, Thailand, Malaysia, India, UAE, Korea Latin America: Colombia and Brazil

Local sales staff allocated in major countries during FY2015

Product strategy tailored to each market






5) Dividend Policy

Basic dividend policy

- Maintain stable and continuous dividend payments while retaining necessary reserves for future business expansion. Retained earnings are used in R&D investments, capital investments, M&A and development of human resources.
- Cash dividends is the base of the shareholder return, and a target consolidated pay-out ratio is 30% or more.
- Share buyback is considered in a flexible manner.



* Effective April 1, 2015, each share of common stock was split into two shares. Dividends per share from FY2006 to FY2014 were actual payment amounts.

Cancellation and repurchase of treasury stock May 20 June 2



Number of treasury stock: 2,070K shares

(stockholding ratio: 2.3%)





Disclaimer:

Contents described in this document are based on the Company's best judgments at the time it was prepared and do not constitute a guarantee or promise that the Company will achieve its numerical targets or implement the measures.